Clinical Trial Update: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) [Phase 2]

View source ↗

Summary

Phase 2 study of bomedemstat in essential thrombocythemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Conditions: Essential Thrombocythemia | Phase 2 | Status: COMPLETED | Results posted: 2024-04-02